Our resources include an extensive panel of hematologic cancer cell lines, featuring commercial models, a unique proprietary collection of multiple myeloma cell lines, and acquired-resistant variants. These models reflect the molecular and clinical heterogeneity observed in patients, including subclones, mutations, and diverse resistance profiles.
Our resources include an extensive panel of hematologic cancer cell lines, featuring commercial models, a unique proprietary collection of multiple myeloma cell lines, and acquired-resistant variants. These models reflect the molecular and clinical heterogeneity observed in patients, including subclones, mutations, and diverse resistance profiles.
Diag2Tec can select the best models to meet specific needs, as most of our cell lines have been thoroughly characterized using genomic datasets (RNA-seq, Exome-seq, SNP analysis, DNA methylation analysis, miRNA and Chip-seq), using clinical (subtypes, cytogenetics) and biological assays (immunophenotypic and IC50 to SOC treatments).
Mechanistic and Functional Readouts
Diag2Tec generates high-value and relevant data:
- Drug sensitivity, cell growth inhibition (IC50 with Cell Titer Glo luminescence assays)
- Combination profiling (synergy matrices)
- Mechanism-of-action and resistance studies (flow cytometry with Annexin, Cell cycle and other customized flow panels)
- Metabolism Profiling: Oxphos/Glycolysis (Seahorse, Flow cytometry, Mass Spectrometry)
- Genomic characterization at baseline and/or after treatments
- Integration with genomic and multi-omics datasets for biomarkers identification
Overcoming Drug Resistance to Standard of Care (SOC)
Diag2Tec specifically leverages resistant models to investigate mechanisms of resistance and identify new therapeutic strategies. Our assays enable the evaluation of novel compounds or combinations to resensitize acquired-resistant cell lines, providing critical insights for overcoming therapeutic escape and improving patient outcomes.
Deliverables
High-quality, decision-ready data packages including comprehensive reports and raw/processed datasets, supporting preclinical development and translational research.
Diag2Tec has privileged access to a large collection of patient-derived primary samples with various hematologic malignancies, including newly diagnosed and relapsed cases, available for ex vivo assay. These samples are from different origins (bone marrow, blood, tissues), and preserve the biological complexity and heterogeneity observed in patients, providing a unique opportunity to assess drug responses in clinically meaningful contexts.
Diag2Tec has privileged access to a large collection of patient-derived primary samples with various hematologic malignancies, including newly diagnosed and relapsed cases, available for ex vivo assay. These samples are from different origins (bone marrow, blood, tissues), and preserve the biological complexity and heterogeneity observed in patients, providing a unique opportunity to assess drug responses in clinically meaningful contexts. As most of primary samples have been thoroughly characterized using RNA-seq from bulk or isolated-tumor cells, and are fully annotated with clinical data (age, gender, cytogenetics, subtypes, history of treatment), Diag2Tec can select the best models to meet specific needs. All primary samples or data are used after patient’s declared consent and following approval of the Ethic Committee. Our partner Biological Resources Centers are certified ISO9001 and ISO 20387.
Mechanistic and Functional Readouts
We generate actionable data through the co-culture of primary samples within their microenvironment :
- Deep phenotyping and immune profiling by multiparametric flow cytometry,
- Ex vivo drug sensitivity profiling (single treatments and combination) with treatment ranging from 24 hours to up to 10 days (20 to 100 conditions depending on models and readouts)
- Evaluation of cytotoxicity and depletion of tumor and non-tumor cells (multiparametric flow cytometry),
- Customized assays with co-culture systems depending of the needs,
- Specific immune-mediated assays (ADCC, ADCP, CDC, Bispecific),
- Cytokines and other soluble factors analyses (Elisa, Proteomic assays)
- Genomic characterization at baseline and/or after treatments,
- Integration with clinical, biological, and multi-omics datasets.
Our resources enables the evaluation of therapeutic agents across a wide range of patient profiles, including resistant and refractory settings. This approach supports the identification of differential responses, mechanisms of resistances, and strategies to overcome them, including resensitization through combination therapies.
Deliverables
High-quality, decision-ready data packages including comprehensive reports and raw/processed datasets, supporting translational research and precision medicine approaches
Diag2Tec provides advanced, human-relevant platform to investigate normal B-cell to plasma cell differentiation, enabling the evaluation of therapeutic strategies in multiple myeloma and autoimmune diseases.
Diag2Tec provides advanced, human-relevant platform to investigate normal B-cell to plasma cell differentiation, enabling the evaluation of therapeutic strategies in multiple myeloma and autoimmune diseases.
Physiologically Relevant Model
The memory B-cell to plasma cell differentiation model recapitulates key maturation stages, from activated B cells to antibody-secreting plasma cells. This system enables the study of plasma cell biology, immunoglobulin production, and cellular dynamics in both normal and disease-relevant contexts. It is particularly relevant for multiple myeloma, as well as autoimmune disorders driven by pathogenic antibody production.
Mechanistic and Functional Readouts
We offer a wide range of assays, including:
- Phenotyping profiling by multiparametric flow cytometry,
- Differentiation and proliferation monitoring (multiparametric flow cytometry, cell count/viability),
- Ex vivo drug sensitivity on the different subsets of cells and on the differentiation process (multiparametric flow cytometry)
- Specific immune-mediated assays (ADCC, ADCP, CDC),
- Immunoglobulin secretion profiling on the different subsets of cells (Multiplex Elisa)
- Cytokines and other soluble factor analysis (Elisa, Proteomic assays)
- Genomic characterization at baseline and/or after treatments,
Deliverables
Comprehensive, decision-ready data packages, including detailed reports and raw/processed datasets, to support preclinical and translational research.
Given the increasingly important role of immunotherapy agents in the treatment of haematological cancers, Diag2Tec developed services to evaluate the efficacy, mechanisms of action, and resistance of immune-based therapies in our hematologic malignancies models (cell lines, primary samples and plasma cell differentiation model.
Given the increasingly important role of immunotherapy agents in the treatment of haematological cancers, Diag2Tec developed services to evaluate the efficacy, mechanisms of action, and resistance of immune-based therapies in our hematologic malignancies models (cell lines, primary samples and plasma cell differentiation model.
Clinically Relevant Models
For these services, Diag2Tec selects the best models according to the needs of the preclinical studies. Diag2Tec leverages a comprehensive portfolio of models, including validated hematologic cancer cell lines, unique proprietary panel of multiple myeloma cell lines, primary samples from patients with hematologic malignancies (Multiple Myeloma, Non-Hodgkin Lymphoma, Acute and Chronic Leukemia…), and our normal plasma cell differentiation model. These systems are enriched with integrated clinical, biological and genomic data ensuring strong translational relevance ((age, gender, subtypes, gene expression profile, mutations, FISH, epigenetic data, treatment and response…).
Assays and Functional Readouts
We provide advanced assays to assess the direct and immune-mediated cytotoxicity (ADCC, ADCP, CDC, Bipsecific) for monoclonal antibodies, bispecifics, trispecifics, and antibody-drug conjugates (ADCs):
- Co-culture systems with PBMCs or specific immune cells from patients or healthy donors (NK, T cells, monocytes)
- Co-culture systems of primary samples within their microenvironment when sufficient to assess immune therapy effects.
- Single-agent and combination treatment strategies
- Viability and targeted depletion of tumor and non-tumor cells via multiparametric flow cytometry
- Immunophenotyping of immune cells (including activation or exhaustion markers) via multiparametric flow cytometry
- Cytokine release analysis from culture supernatants
- Customized assays on request
Deliverables
High-quality, decision-ready data packages including comprehensive reports, as well as raw and processed datasets to support preclinical and translational development.